Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year. Treatment 3/6/2025
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
View this post in the Community →
Similar Community Posts Join
5 / 110 resultscommunity CASSIOPEA ANNOUNCES VERY POSITIVE PHASE II TWELVE MONTHS RESULTS FOR BREEZULA® (CLASCOTERONE) IN TREATING ANDROGENETIC ALOPECIA
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
community BREEZULA COVID UPDATE: Filing for Special Protocol Assessment with FDA
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
community Cassiopea Announces Very Positive Interim Analysis Phase 2 Results for Breezula® (Clascoterone) in Treating Androgenetic Alopecia
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
community First patient dosed with Pyrilutamide (Kintor) Phase III
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
Related Research
6 / 61 results
research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
Topical therapies show promise for hair loss and acne treatment with minimal side effects.
research Industry Update: The Latest Developments in the Field of Therapeutic Delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research New Drugs Under Investigation for the Treatment of Alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Androgenetic Alopecia: An Update Of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research Antiandrogens and Androgen Inhibitors in Dermatologic Treatments
Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
research Cell Therapy for Androgenetic Alopecia: Elixir or Trick?
Stem cell therapies could be a promising alternative for hair loss treatment, but more research is needed to understand their full potential and safety.